Form 4: Moderna CFO Reports Routine Stock Transactions

Moderna's Chief Financial Officer, James M. Mock, reported the acquisition of common stock through RSU conversions and subsequent sales to cover tax obligations.

Summary

• Moderna's CFO, James M. Mock, acquired 774 shares of common stock on August 27, 2025, and 329 shares on August 28, 2025, through the conversion of Restricted Stock Units (RSUs).
• To satisfy tax withholding obligations related to these RSU vestings, Mr. Mock disposed of 375 shares at $24.73 per share on August 27, 2025, and 160 shares at $25.10 per share on August 28, 2025.
• Following these transactions, Mr. Mock directly beneficially owns 17,509 shares of Moderna common stock.
• The RSUs convert into common stock on a one-for-one basis.
• One RSU award (774 shares) had 25% vest on February 27, 2025, with the remainder vesting in twelve equal quarterly installments.
• Another RSU award (329 shares) had 25% vest on February 28, 2024, with the remainder vesting in twelve equal quarterly installments.

Sentiment

Score: 5

Explanation: Neutral. The filing reports routine insider transactions related to equity compensation and tax obligations, which are standard and do not indicate significant positive or negative developments for the company.

Positives

• The transactions represent the vesting of previously granted equity awards, indicating the retention and long-term incentive structure for the CFO.

Negatives

• The disposition of shares to cover tax obligations, while routine, slightly reduces the CFO's direct beneficial ownership in the short term.

Future Outlook

The filing indicates ongoing vesting schedules for Restricted Stock Units, with remaining installments for one award continuing quarterly after February 27, 2025, and for another after February 28, 2024.

Industry Context

These routine insider transactions, involving the vesting of equity awards and subsequent tax-related sales, are common practice across the biotechnology and pharmaceutical industries for executive compensation. They do not reflect a change in strategic direction or operational performance but rather the standard execution of long-term incentive plans.

Related Party Transactions

• The reported transactions involve the Chief Financial Officer, James M. Mock, acquiring shares from Moderna, Inc. through RSU conversions and subsequently selling shares to cover tax liabilities, which are considered related party transactions in the context of insider dealings.

Stakeholder Impact

• Shareholders: Minor dilution from RSU vesting is offset by the retention of key management. The transactions are routine and unlikely to significantly impact shareholder value.
• Employees: Reinforces the company's equity compensation structure for executives.
• Management: The transactions reflect the realization of long-term incentive compensation for the CFO.

Next Steps

• Continued vesting of remaining Restricted Stock Unit installments as per the established schedules.

Key Dates

Recommendation

The filing details routine insider transactions related to executive compensation (RSU vesting and tax-related sales). These are standard occurrences and do not provide new material information that would warrant a change in investment recommendation. The transactions reflect the execution of pre-existing compensation plans rather father than a discretionary investment decision by the insider. Therefore, a 'hold' recommendation is appropriate as the filing does not present a catalyst for a 'buy' or 'sell' decision.

Keywords

Moderna, MRNA, SEC Form 4, Insider Trading, Stock Transaction, Restricted Stock Units, CFO, Equity Compensation, Tax Withholding